RSD

We propose to establish a Centre of Excellence in Digital Health and Personalised Medicine (CLINNOVA), addressing future medical and societal needs. A prerequisite for personalised medicine is the establishment of clinical research in Luxembourg, the current weakness that we would like to overcome with the programme. The Centre will build on the previous investments into fundamental biomedical research and link to the hospitals in Luxembourg to ensure that innovation from the bench will reach the clinic and patient care. The Centre will fully incorporate personalised medicine approaches integrating medical history from eHealth records with newly generated molecular and phenotypic data as well as environmental and/or health data from mobile devices. Teaming up with the Center for Innovativ Medicinsk Teknologi, Region Syddanmark (CIMT-RSD) and the Nationale Centrum für Tumorerkrankungen, Deutsches Krebsforschungszentrum (NCT-DKFZ) will allow us to benefit from the immense experience and world-leadership has in setting up modern eHealth infrastructures and translational cancer research. We will focus on areas where there is both existing excellence in pre-clinical research and an important clinical unmet need, namely the disease areas of cancer and neurodegenerative diseases with the transversal axis immunology as important element in both disease areas. Environmental, nutritional and social influences interpreted together with the medical history of patients and molecular diagnostic information will be key to gain an understanding of the diseases for the individual person. A strong ICT component will be a major success factor: data integration and interpretation are needed to derive computational models and predictions on disease development. The Centre will combine all aspects of technological innovation with clinical care and bring innovations to patients and doctors serving as an attractor for companies and further develop the local ecosystem.

Millions of Europeans undergo optical colonoscopy (OC) every year. OC may be associated with discomfort, complications and sick-days, which affect acceptability, and constitutes a heavy burden on European hospital capacities. Colon capsule endoscopy (CCE) is a new technology, which has the potential to replace 50 ? 65 % of all OCs. CCE is preferred by patients, has a lower complication rate and can be performed out of hospital. CCE holds great potential for both patients and hospitals. However, the diagnostic process of CCE includes a time-consuming manual reading done by trained personnel and is expensive and prone to human error. For CCE to be a viable alternative to OC these challenges need to be addressed. Thus, our goal is to create a complete and validated AI-assisted pathway that improves CCE diagnostics making the technology clinically viable for the good of patients, health care systems and society. We have already completed development of several AI algorithms (AIA) for CCE diagnostics, and more will be completed within 1 ?2 years. The AICE concept will focus on: 1) completing development of the remaining AIAs, 2) external validation the all AIAs, 3) creating a clinical support system for data handling, storage and transmission, 4) developing a diagnostic pathway that considers quality, efficiency, patient preferences, ethics and economy 5) promotes the integration of AICE solutions into clinical practice via guidelines and upscaling adjustments. To achieve these goals, AICE will use an unprecedented large and diverse collection of existing patient data from nation-wide clinical studies, and will include extensive initiatives in the fields of ethics, communication and patient engagement. To ensure the right competences are present, AICE brings together clinical researchers, epidemiologists, data scientists, digital health experts, health economists, ethics researchers, SMEs, communication experts and experts in regulatory affairs.

Disability related to incurable cancer affects over a million Europeans each year. Our objective is to test the clinical and cost effectiveness of an integrated short-term palliative rehabilitation intervention, to improve function and quality of life in people affected by incurable cancer. At the core of INSPIRE is a multinational randomised controlled trial across five European countries. We will recruit 340 participants to assess the clinical and cost-effectiveness of palliative rehabilitation on quality of life, disability, symptom burden and goal attainment in people with incurable cancer. If positive, the trial could result in a scalable and equitable intervention that improves function and quality of life in people with incurable cancer, and reduces the burden of care for their families. The intervention can be adapted and integrated into different health systems using existing staff and services, with little or no additional cost. To support our ambition to make palliative rehabilitation part of routine care for people with incurable cancer we also conduct: - comparative analysis of health services to understand current integration of rehabilitation across oncology and palliative care services; - mixed-method evaluations of equity and inclusivity, processes and implementation for the intervention, at patient, health service and health system levels; - evidence synthesis and a Delphi consensus on indicators, core interventions, outcomes, and integration methods, to develop a framework for palliative rehabilitation practice and policy. The INSPIRE consortium brings together leaders in palliative care, oncology and rehabilitation from Nordic, Southern and Northern European countries, with complementary expertise in health services research, trials of complex interventions, mixed method evaluations, statistics and economics. We are partnering with European civil society organisations to ensure citizen engagement and dissemination at the highest level.